Kamila M. Śledź

Kamila M. Śledź

Auto-generated profile, based on publicly available information

Kamila M. Śledź

School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, Bristol, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
JTJustin S. Trory
Justin S. Trory
AMAttila Munkacsi
Attila Munkacsi
KŚKamila M. Śledź
Kamila M. Śledź
JVJordan Vautrinot
Jordan Vautrinot
LGLucy J. Goudswaard
Lucy J. Goudswaard
IHIngeborg Hers
Ingeborg Hers

30 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JTJustin S. Trory
Justin S. Trory
AMAttila Munkacsi
Attila Munkacsi
KŚKamila M. Śledź
Kamila M. Śledź
LGLucy J. Goudswaard
Lucy J. Goudswaard
KHKate Heesom
Kate Heesom
IHIngeborg Hers
Ingeborg Hers
The tyrosine kinase BTK plays an important role in platelet function downstream of GPVI and CLEC2 receptors and has been proposed as a novel target to prevent thrombosis in patients that are at increased risk. However, current clinically approved BTK inhibitors have off target effects and are associated with an increased bleeding risk. In this study, we therefore explored whether BTK can be targeted for degradation in human platelets by using recently developed heterobifunctional molecules that employ the proteasomal system to break down BTK. Here we confirm that human platelets are highly susceptible to BTK degraders with the generic tyrosine kinase degrader TL12-186, and the BTK degraders DD-04-15 and DD-03-171 leading to breakdown of BTK and its closely related kinase TEC, an effect that was prevented by proteasomal inhibitors. Tandem Mass Tag proteomic analysis confirmed high selectivity with TL12-186 degrading BTK/TEC, FAK/PYK2 and FER, whereas DD-04-15 and DD-03-171 degraded BTK/TEC only. GPVI-mediated platelet integrin α IIb β 3 activation, P-selectin expression, and phosphatidyl-serine exposure were largely impaired upon BTK/TEC degradation, with PAR-1-mediated responses left intact. This is the first study to demonstrate that chemical protein degraders can be successfully employed in anucleate human platelets to modulate their function.